.Pharmacolibrary.Drugs.ATC.B.B02BD30

Information

Thrombin is a serine protease enzyme that plays a central role in the coagulation cascade, converting fibrinogen to fibrin and thus promoting blood clot formation. It is used medicinally as a topical hemostatic agent to control bleeding during surgeries or trauma. Thrombin for systemic use is not approved due to its rapid neutralization by antithrombin and potential for severe coagulopathy.

Pharmacokinetics

Estimated pharmacokinetic parameters for exogenous human thrombin administered intravenously in healthy adult patients, as direct clinical PK studies are not available.

References

1. Zhang, DM, et al., & Cui, YM (2012). Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers. Acta pharmacologica Sinica 33(11) 1387–1394. DOI:10.1038/aps.2012.37 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22659624

2. Bateman, RM, et al., & Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. Critical care (London, England) 20(Suppl 2) 94–None. DOI:10.1186/s13054-016-1208-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27885969

3. Dash, D (2015). Current Status of Antiplatelet Therapy in Acute Coronary Syndrome. Cardiovascular & hematological agents in medicinal chemistry 13(1) 40–49. DOI:10.2174/187152571301150730114514 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26245659

Revisions

• 06/2025 initial generated model